| Download Abstract: | 0232-Esquenazi-Movement-Disorders.docx |
|---|---|
| Abstract Title | A randomized, double-blind, head-to-head, crossover study comparing the clinical safety and efficacy of abobotulinumtoxinA with onabotulinumtoxinA when treating adults with upper limb spasticity |
| First Author | Dr. Alberto Esquenazi |
| Status | Rejected |
| Comments to Author | The Results indicate: "AboBoNT-A lasted significantly longer than onaBoNT-A (adjusted mean duration of 99.3 days [80% CI: 96.9; 101.7] versus 96.3 days [80% CI: 93.9; 98.7], respectively), with an adjusted difference in duration for aboBoNT-A – onaBoNT-A of 3.0 [80% CI: 0.2, 5.9] days, p=0.17 (statistically significant based on a two-sided αlpha of 0.20)." The difference in duration of 3 days seems clinically non-significant, and the P value of 0.17 similarly appears non-significant Authors should clarify above issues in over-stating the "longer duration" claim |
| Reviewer | Simpson |
| Reviewer Notes | Above issues in Comments to Authors requires response |
| Request Secondary Reviewer |
|